Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip

Dizziness is a listed side effect of most GLP‑1 drugs, and it usually has one of three sources: blood pressure falling, blood sugar falling, or the rough first weeks of a dose increase. The labels handle two of those differently. They tell prescribers to consider lowering insulin or sulfonylurea doses. They say nothing of the kind about blood-pressure pills, even though their own figures show low blood pressure is more common in the people taking them.

How often it happens, by drug

Each label reports dizziness from its own placebo-controlled trials, so read each row against its own placebo column rather than comparing the drugs.^[2][1][4][3]

Two things stand out. Dizziness barely moves with the tirzepatide dose. And the Ozempic label mentions it only in a line of other reactions above 0.4%, while Mounjaro’s trial table, which starts at 5%, does not list it at all.^[5][6] Saxenda’s label adds the most useful timing detail: dizziness was reported mainly within the first 12 weeks, and often alongside nausea, vomiting or diarrhea.^[4]

Where it comes from

Blood pressure falling

These drugs lower blood pressure,^[7] and sometimes further than intended. On Wegovy, reactions related to low blood pressure were reported in 1.3% of adults against 0.4% on placebo, and fainting in 0.8% against 0.2%; the label ties some of them to stomach side effects and fluid loss.^[1] On Zepbound, low blood pressure occurred in 1.6% against 0.1%, and the label says it also occurred alongside stomach side effects and dehydration.^[2]

The largest look at the tirzepatide trial data found dizziness was the most common blood-pressure-related side effect: 4.6% on tirzepatide against 2.3% on placebo. Fainting was not more common, 0.5% against 0.8%. Blood pressure fell fastest over the first 24 weeks, which is the period of dose increases, and then leveled off.^[7] A 2026 analysis of 32 randomized trials found tirzepatide raised the risk of low-blood-pressure events (relative risk 2.45), while the increase with semaglutide was not statistically significant.^[9] What the blood-pressure fall means for heart health is covered in what else GLP-1 drugs change.

Blood sugar falling

Every Medication Guide includes “dizziness or light-headedness” in its list of low-blood-sugar warning signs, and names insulin or a sulfonylurea as what raises the risk.^[2] On the Zepbound label, low blood sugar was reported by 10.3% of people also taking a sulfonylurea against 2.1% of those who were not.^[2] Who is actually at risk is worked through in GLP-1 drugs and low blood sugar.

The instruction the labels leave out

For blood sugar, the labels say what to do. Zepbound’s says cutting the insulin or sulfonylurea dose can bring the low-blood-sugar risk down.^[2] For blood pressure there is no equivalent. The only mention of blood-pressure medicines in any of these labels is a finding, not an instruction: low blood pressure was more common in people also on one. On Zepbound that was 2.2% against 1.2%; on Foundayo, 4% against 1%; Wegovy says it was more frequent without giving figures.^[2][3][1]

The trials show the adjustment happening anyway. Across the STEP semaglutide trials, 17.7% of people on blood-pressure medicines stopped all of them on semaglutide, against 9.0% on placebo, and 16.5% reduced them against 4.8%. The authors noted that doctors are not used to cutting these drugs back, “especially as there are no guidelines to provide direction in the absence of hypotension or other adverse effect.”^[8] For tirzepatide there is no comparable record: the main trial let investigators adjust blood-pressure drugs but “did not collect robust information on medication changes.”^[7]

When dizziness is urgent

• Fainting or feeling dizzy together with a swollen face or throat, difficulty breathing, or a very rapid heartbeat. The Zepbound Medication Guide lists these as signs of a serious allergic reaction: stop the drug and get medical help right away.^[2]
• Dizziness with sweating, shakiness or confusion while taking insulin or a sulfonylurea. These are low-blood-sugar signs, and the Medication Guides tie that risk to those medicines.^[2]
• Vomiting or diarrhea that will not stop. The labels warn that the fluid loss can injure the kidneys; see GLP-1 diarrhea and GLP-1 drugs and your kidneys.
• A racing heartbeat at rest. Wegovy’s label asks patients to tell their prescriber about palpitations or a racing heart while resting.^[1] Why a GLP-1 raises your heart rate covers which labels warn about it and which do not.